Literature DB >> 9302367

Acromegaly, colonic polyps and carcinoma.

P J Jenkins1, P D Fairclough, T Richards, D G Lowe, J Monson, A Grossman, J A Wass, M Besser.   

Abstract

OBJECTIVE: It has been suggested that patients with acromegaly may be at risk of developing colorectal carcinoma. In order to clarify this issue, we have evaluated the prevalence of carcinoma, premalignant tubulovillous adenomas and hyperplastic colonic polyps in a large cohort of patients with acromegaly.
DESIGN: Prospective colonoscopic examination by a single operator. PATIENTS: One hundred and twenty-nine patients with biochemically proven acromegaly.
RESULTS: At least one lesion was visualized in 63 patients. Adenocarcinoma was present in six patients (5%), but only two had symptoms; all lesions were endoscopically obvious. Compared with a normal group, the odds ratio of colorectal cancer is increased at 13.5 (95% confidence intervals (c.i.) 3.1-75). One or more tubulovillous adenoma was found in 34 patients (26%) and this prevalence was age-dependent, occurring in 39% of patients aged 70 years or over. Comparing the prevalence of left-sided colonic adenomas with that in a normal group, there is a higher prevalence among patients over 49 years with an odds ratio of 4.2 (95% c.i. 2.5-6.8). Patients with acromegaly who had an adenoma were significantly older than unaffected patients (61.9 vs 54.1 years; P < 0.001) but had similar GH and IGF-1 levels and duration of disease.
CONCLUSIONS: Patients with acromegaly have an increased risk of developing colorectal cancer and a significantly higher prevalence of tubulovillous adenomas compared with normal subjects. Routine surveillance colonoscopy is indicated in this group of patients.

Entities:  

Mesh:

Year:  1997        PMID: 9302367     DOI: 10.1046/j.1365-2265.1997.1911029.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  40 in total

1.  Colorectal neoplasia in acromegaly.

Authors:  P J Jenkins; G M Besser; P D Fairclough
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

Review 2.  The role of circulating IGF-I: lessons from human and animal models.

Authors:  Shoshana Yakar; Yiping Wu; Jennifer Setser; Clifford J Rosen
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

Review 3.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

4.  High magnification chromoscopic colonoscopy as a screening tool in acromegaly.

Authors:  D P Hurlstone; S S Cross; A J Lobo; D S Sanders
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

5.  Screening guidelines for colorectal cancer and polyps in patients with acromegaly.

Authors:  P J Jenkins; P D Fairclough
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

6.  Effects of growth factors and receptor blockade on gastrointestinal cancer.

Authors:  R J Playford; H Wassan; S Ghosh
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

7.  Serum factors associated with precancerous colonic lesions in acromegaly.

Authors:  M Lombardi; I Scattina; C Sardella; C Urbani; E Marciano; S Signori; L Ruocco; G Pellegrini; E Martino; F Bogazzi
Journal:  J Endocrinol Invest       Date:  2013-01-14       Impact factor: 4.256

8.  Colorectal neoplasm and acromegaly.

Authors:  Anil Bhansali; Pinaki Dutta; Mohammad Hayat Bhat; S K Sinha; R Kochar; K Vaiphi
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

9.  Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis.

Authors:  Theodoros Rokkas; Dimitrios Pistiolas; Panos Sechopoulos; Georgios Margantinis; Georgios Koukoulis
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

10.  Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans.

Authors:  M Mazen Jamal; Eugene J Yoon; Kenneth J Vega; Mehrtash Hashemzadeh; Kenneth J Chang
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.